Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (809)	5/13/1998 5:25:00 PM
From: crysball	Read Replies (1) \| Respond to of 1491

Shalom Ariela, Yosi, David, Zvi et al, Recently communicated a 'hidden market ' for Lotemxax to PARS....each year 35,000 Americans are fitted with scleral shells and/or ocular prosthesis by Ocuists, who work in conjuction with Opthamologists [but have separate practices]. The nice aspect of this market segment, every patient is a potential life-time user of Lotemax, since the scleral shell presents a long term source of irritation to both the Sclera and Conjunctiva, which when treated by conventional steroids [Inflamase Forte]can result in an elevation of introcular pressure. Don't know the annual numbers for Europe, Canada etc, or the total US populationm but that's what the BOL/ Storitz folks can followup. Also anticipate obtaining from my Opthamologist tomorrow what may be the first 'commercial' prescription for Lotemax..........which may some day have historical significance at a PARS stockholder meeting when we can all meet and discuss the 'first real $' PARS ever earned.